Literature DB >> 19914603

Brain region specific actions of regulator of G protein signaling 4 oppose morphine reward and dependence but promote analgesia.

Ming-Hi Han1, Willam Renthal, Robert H Ring, Zia Rahman, Kassi Psifogeorgou, David Howland, Shari Birnbaum, Kathleen Young, Rachael Neve, Eric J Nestler, Venetia Zachariou.   

Abstract

BACKGROUND: Regulator of G protein signaling 4 (RGS4) is one of the smaller members of the RGS family of proteins, which are known to control signaling amplitude and duration via interactions with G protein alpha subunits or other signaling molecules. Earlier evidence suggests dynamic regulation of RGS4 levels in neuronal networks mediating actions of opiates and other drugs of abuse, but the consequences of RGS4 actions in vivo are largely unknown.
METHODS: In this study, we use constitutive and nucleus accumbens-inducible RGS4 knockout mice as well as mice overexpressing RGS4 in the nucleus accumbens via viral mediated gene transfer, to examine the influence of RGS4 on behavioral responses to opiates. We also use electrophysiology and immunoprecipitation assays to further understand the mechanisms underlying the tissue-specific actions of RGS4.
RESULTS: Inducible knockout or selective overexpression of RGS4 in the nucleus accumbens reveals that, in this brain region, RGS4 acts as a negative regulator of morphine reward, whereas in the locus coeruleus RGS4 opposes morphine physical dependence. In contrast, we show that RGS4 does not affect morphine analgesia or tolerance but is a positive modulator of certain opiate analgesics, such as methadone and fentanyl.
CONCLUSIONS: These findings provide fundamentally novel information concerning the role of RGS4 in the cellular mechanisms underlying the diverse actions of opiate drugs in the nervous system. Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19914603      PMCID: PMC3077672          DOI: 10.1016/j.biopsych.2009.08.041

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  65 in total

Review 1.  Drug addictions. Molecular and cellular endpoints.

Authors:  M J Kreek
Journal:  Ann N Y Acad Sci       Date:  2001-06       Impact factor: 5.691

2.  RGS9 modulates dopamine signaling in the basal ganglia.

Authors:  Zia Rahman; Johannes Schwarz; Stephen J Gold; Venetia Zachariou; Marc N Wein; Kwang Ho Choi; Abraham Kovoor; Ching Kang Chen; Ralph J DiLeone; Sigrid C Schwarz; Dana E Selley; Laura J Sim-Selley; Michel Barrot; Robert R Luedtke; David Self; Rachael L Neve; Henry A Lester; Melvin I Simon; Eric J Nestler
Journal:  Neuron       Date:  2003-06-19       Impact factor: 17.173

3.  Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia.

Authors:  K Mirnics; F A Middleton; G D Stanwood; D A Lewis; P Levitt
Journal:  Mol Psychiatry       Date:  2001-05       Impact factor: 15.992

4.  Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease.

Authors:  P K Tekumalla; F Calon; Z Rahman; S Birdi; A H Rajput; O Hornykiewicz; T Di Paolo; P J Bédard; E J Nestler
Journal:  Biol Psychiatry       Date:  2001-11-15       Impact factor: 13.382

5.  The mu opioid agonist DAMGO stimulates cAMP production in SK-N-SH cells through a PLC-PKC-Ca++ pathway.

Authors:  Vardit Rubovitch; Mikhal Gafni; Yosef Sarne
Journal:  Brain Res Mol Brain Res       Date:  2003-02-20

6.  Striatal gene expression of RGS2 and RGS4 is specifically mediated by dopamine D1 and D2 receptors: clues for RGS2 and RGS4 functions.

Authors:  Jean-Marc Taymans; Josée E Leysen; Xavier Langlois
Journal:  J Neurochem       Date:  2003-03       Impact factor: 5.372

Review 7.  Cellular regulation of RGS proteins: modulators and integrators of G protein signaling.

Authors:  Susanne Hollinger; John R Hepler
Journal:  Pharmacol Rev       Date:  2002-09       Impact factor: 25.468

8.  RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease.

Authors:  Stephen J Gold; Chau V Hoang; Bryan W Potts; Gregory Porras; Elsa Pioli; Ki Woo Kim; Agnes Nadjar; Chuan Qin; Gerald J LaHoste; Qin Li; Bernard H Bioulac; Jeffrey L Waugh; Eugenia Gurevich; Rachael L Neve; Erwan Bezard
Journal:  J Neurosci       Date:  2007-12-26       Impact factor: 6.167

9.  Abused drugs modulate RGS4 mRNA levels in rat brain: comparison between acute drug treatment and a drug challenge after chronic treatment.

Authors:  G B Bishop; W E Cullinan; E Curran; H B Gutstein
Journal:  Neurobiol Dis       Date:  2002-08       Impact factor: 5.996

10.  Regulation of RGS proteins by chronic morphine in rat locus coeruleus.

Authors:  Stephen J Gold; Ming-Hu Han; Amy E Herman; Yan G Ni; Cindy M Pudiak; George K Aghajanian; Rong-Jian Liu; Bryan W Potts; Susanne M Mumby; Eric J Nestler
Journal:  Eur J Neurosci       Date:  2003-03       Impact factor: 3.386

View more
  39 in total

1.  A unique role of RGS9-2 in the striatum as a positive or negative regulator of opiate analgesia.

Authors:  Kassi Psifogeorgou; Kassi Psigfogeorgou; Dimitra Terzi; Maria Martha Papachatzaki; Artemis Varidaki; Deveroux Ferguson; Stephen J Gold; Venetia Zachariou
Journal:  J Neurosci       Date:  2011-04-13       Impact factor: 6.167

2.  Regulators of G protein signaling (RGS) proteins as drug targets: modulating G-protein-coupled receptor (GPCR) signal transduction.

Authors:  David L Roman; John R Traynor
Journal:  J Med Chem       Date:  2011-09-29       Impact factor: 7.446

3.  Nucleus accumbens-specific interventions in RGS9-2 activity modulate responses to morphine.

Authors:  Sevasti Gaspari; Maria M Papachatzaki; Ja Wook Koo; Fiona B Carr; Maria-Efstratia Tsimpanouli; Eugenia Stergiou; Rosemary C Bagot; Deveroux Ferguson; Ezekiell Mouzon; Sumana Chakravarty; Karl Deisseroth; Mary Kay Lobo; Venetia Zachariou
Journal:  Neuropsychopharmacology       Date:  2014-02-24       Impact factor: 7.853

4.  RGS9-2 Modulates Responses to Oxycodone in Pain-Free and Chronic Pain States.

Authors:  Sevasti Gaspari; Valeria Cogliani; Lefteris Manouras; Ethan M Anderson; Vasiliki Mitsi; Kleopatra Avrampou; Fiona B Carr; Venetia Zachariou
Journal:  Neuropsychopharmacology       Date:  2017-01-11       Impact factor: 7.853

5.  Inhibition of the regulator of G protein signalling RGS4 in the spinal cord decreases neuropathic hyperalgesia and restores cannabinoid CB1 receptor signalling.

Authors:  Barbara Bosier; Pierre J Doyen; Amandine Brolet; Giulio G Muccioli; Eman Ahmed; Nathalie Desmet; Emmanuel Hermans; Ronald Deumens
Journal:  Br J Pharmacol       Date:  2015-10-25       Impact factor: 8.739

6.  Opioid-induced down-regulation of RGS4: role of ubiquitination and implications for receptor cross-talk.

Authors:  Qin Wang; John R Traynor
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

Review 7.  The Opioid Crisis and the Future of Addiction and Pain Therapeutics.

Authors:  Nathan P Coussens; G Sitta Sittampalam; Samantha G Jonson; Matthew D Hall; Heather E Gorby; Amir P Tamiz; Owen B McManus; Christian C Felder; Kurt Rasmussen
Journal:  J Pharmacol Exp Ther       Date:  2019-09-03       Impact factor: 4.030

Review 8.  Regulators of G Protein Signaling in Analgesia and Addiction.

Authors:  Farhana Sakloth; Claire Polizu; Feodora Bertherat; Venetia Zachariou
Journal:  Mol Pharmacol       Date:  2020-05-30       Impact factor: 4.436

9.  The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors.

Authors:  Isaac J Dripps; Qin Wang; Richard R Neubig; Kenner C Rice; John R Traynor; Emily M Jutkiewicz
Journal:  Psychopharmacology (Berl)       Date:  2016-09-13       Impact factor: 4.530

Review 10.  R4 Regulator of G Protein Signaling (RGS) Proteins in Inflammation and Immunity.

Authors:  Zhihui Xie; Eunice C Chan; Kirk M Druey
Journal:  AAPS J       Date:  2015-11-23       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.